Company / PP&E (Net)
Outlook Therapeutics, Inc. PP&E (Net) History
FY2016-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest PP&E (Net)
$327.2K
FY2020
5-year range
$327.2K / $18.5M
FY2016-FY2020
Trend
-89.7%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $18M to $327,249 over the past 2 years.
Based on SEC 10-K filings.
$327,249 in FY2020 with a 3-year CAGR of -72.7%.
Declined from $18M to $327,249 over the past 2 years.
PP&E (Net) over time
Growth rates
- 3-Year CAGR
- -72.7%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -72.7%, indicating a declining trend.
- In FY2020, pp&e (net) decreased 89.7% year-over-year.
- Peak pp&e (net) was recorded in FY2018.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | PP&E (Net)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2020 | $327.2K | -89.7% |
| FY2019 | $3.2M | -82.8% |
| FY2018 | $18.5M | +14.9% |
| FY2017 | $16.1M | -5.1% |
| FY2016 | $17.0M | - |
As of FY2020 · SEC 10-K · Updated Jun 28, 2026